

About us
A Riyadh-based, SFDA-licensed partner for international pharmaceutical manufacturers since 2022.
About Pharma Solutions
Our facilities
SFDA-licensed warehousing and cold chain in Riyadh and Jeddah.
Services
Seven services covering everything a product needs in the Kingdom, from dossier to hospital shelf.
All services
NUPCO tendering
The fastest route to volume in Saudi public hospitals.
Therapeutic areas
Six areas where licensing, cold chain and specialist relationships matter most.
All therapeutic areas
Top 5
In narcotic medicines
NUPCO Tender and Direct Purchase Awards, 2025.

Take a product from dossier to hospital shelf with us, or use only the services you need.
Most partners use the full route. Each step is also available on its own.
We screen products against Saudi demand, NUPCO tender calendars and competing registrations.
CTD gap analysis, Arabic labelling and eCTD submission, managed by our in-house regulatory affairs team.
SFDA pricing, then listing on NUPCO and private hospital formularies.
Participation in NUPCO and government health cluster tenders.
Scientific office and medical engagement with key prescribers and P&T committees.
Pharmacovigilance and safety reporting, cold-chain distribution and continuity of supply.
One accountable partner, with direct CEO oversight of every partner portfolio.
Every product sold in Saudi Arabia needs a Saudi Food and Drug Authority (SFDA) marketing authorisation, and a foreign manufacturer cannot apply alone. It needs a licensed local partner to submit, answer the agency and hold the registration.
We act as that partner. We assemble the Common Technical Document from your existing files, adapt it to SFDA requirements, submit it and handle every query the agency raises until the product is approved.

Most registration delays come from gaps found late. We review your dossier against current SFDA guidelines before anything is submitted, so missing data, outdated stability studies or labelling problems are fixed on your timetable rather than the agency’s.
Our regulatory team handles the Arabic translation of key documents, including patient information leaflets and pack artwork, and publishes the final submission in eCTD format.

Registration is the start of a product’s life in the Kingdom, not the end. Manufacturing site changes, new pack sizes, new strengths and safety updates all need SFDA approval before they reach the market.
We track every registration we hold, file variations as your product changes, and manage renewals well ahead of expiry so supply is never interrupted by paperwork.

In Saudi Arabia the largest buyer of medicines is the government. Most public hospitals buy through NUPCO, the national unified procurement company, in centralised tenders that only qualified local suppliers can enter.
We bid in NUPCO tenders on behalf of the manufacturers we represent and hold direct supply relationships with Ministry of Health facilities, military and security hospitals, and leading private healthcare groups. For a foreign manufacturer, this is usually the fastest route to meaningful volume in the Kingdom.

NUPCO
National Unified Procurement Company, the central buyer for most public hospitals in the Kingdom.
Prescribers in the Kingdom expect scientific support from the companies whose products they use. SFDA rules require foreign manufacturers promoting medicines locally to operate through a registered scientific office with a qualified manager.
We set up that office for you, appoint the SO-Manager, and run healthcare professional engagement and medical information under the same compliance framework as the rest of our operations.

Every marketed product needs a local system to collect, assess and report adverse events to the SFDA. We provide a dedicated pharmacovigilance function with a local qualified person, so safety obligations in the Kingdom are met from the day your product launches.

Our SFDA-licensed warehouses in Riyadh and Jeddah store products in controlled zones, including refrigerated storage and a licensed vault for narcotics and controlled substances.
A temperature-controlled fleet with continuous monitoring delivers to hospitals, pharmacies and government facilities in more than ten cities, with on-time, in-full performance at or above 95%, measured over 2024–2025.

Tell our business development team what you make and where it is registered today. We will come back to you with a proposed route to market.